HOME PRODUCTS SERVICES COMPANY CONTACT FAQ

Aztreonam

A monocyclic beta-lactam antibiotic originally isolated from Chromobacterium violaceum. It is resistant to beta-lactamases and is used in gram-negative infections, especially of the meninges, bladder, and kidneys. It may cause a superinfection with gram-positive organisms.

Also Known As:

Az-threonam; Azactam; Azthreonam; Bristol-Myers Squibb Brand of Aztreonam; Esteve Brand of Aztreonam; SQ-26,776; Sanofi Winthrop Brand of Aztreonam; Squibb Brand of Aztreonam; Urobactam; Az threonam; Aztreonam Esteve Brand; Aztreonam Squibb Brand; Bristol Myers Squibb Brand of Aztreonam; SQ 26,776; SQ26,776; Propanoic acid, 2-(((1-(2-amino-4-thiazolyl)-2-((2-methyl-4-oxo-1-sulfo-3-azetidinyl)amino)-2-oxoethylidene)amino)oxy)-2-methyl-, (2S-(2alpha,3beta(Z)))-

Networked: 595 relevant articles (107 outcomes, 134 trials/studies)

Relationship Network

Drug Context: Research Results

Experts

1.	Montgomery, A Bruce: 7 articles (01/2015 - 11/2008)
2.	Retsch-Bogart, George Z: 7 articles (05/2014 - 07/2006)
3.	Gibson, Ronald L: 6 articles (10/2011 - 07/2006)
4.	Quittner, Alexandra L: 5 articles (01/2015 - 11/2008)
5.	Oermann, Christopher M: 5 articles (03/2013 - 11/2008)
6.	Thye, Dirk: 5 articles (05/2012 - 10/2007)
7.	Lewis, Sandra A: 4 articles (01/2015 - 03/2013)
8.	Burns, Jane L: 4 articles (05/2014 - 07/2006)
9.	McCoy, Karen S: 4 articles (10/2011 - 11/2008)
10.	Talbot, George H: 4 articles (11/2010 - 10/2007)

Related Diseases

1.	Infection 09/01/1989 - "Clinical study in adults has shown aztreonam to be highly effective against infections of the urinary and lower respiratory tracts, the musculoskeletal system and the female genitourinary tract. " 05/01/1988 - "Aztreonam has proven to be effective, safe therapy for serious and life-threatening infections caused by multiresistant aerobic gram negative bacteria. " 09/01/1985 - "Therefore, Aztreonam is very effective and safe for complicated UTI, especially gram-negative infections." 01/01/1989 - "The concurrent administration of DMDTC and aztreonam offers considerable promise in the treatment of overwhelming pseudomonal infections in mice and may prove to be of value in human patients as well." 02/01/1989 - "[Evaluation of the therapeutic efficacy of aztreonam in the treatment of infection caused by sensitive microorganisms]."
2.	Urinary Tract Infections (Urinary Tract Infection) 10/01/1986 - "It is concluded from these data that aztreonam is highly effective and well tolerated in patients affected either by upper or lower urinary tract infections." 08/01/1986 - "At the dosage used, aztreonam proved effective for severe urinary tract infections caused by members of the family Enterobacteriaceae in pediatric patients." 03/01/1993 - "[The efficacy of aztreonam in a "bolus dose" in the therapy of urinary tract infections in neonates]." 12/01/1988 - "[Clinical efficacy of aztreonam in patients with complicated urinary tract infections]." 01/01/1987 - "The results confirm the efficacy of azthreonam for treatment of urinary tract infection. "
3.	Cystic Fibrosis (Mucoviscidosis) 02/01/2015 - "Evidence for the efficacy of aztreonam for inhalation solution in the management of Pseudomonas aeruginosa in patients with cystic fibrosis." 04/01/1987 - "Efficacy of aztreonam in pulmonary exacerbations of cystic fibrosis." 01/01/2015 - "Open label study of inhaled aztreonam for Pseudomonas eradication in children with cystic fibrosis: The ALPINE study." 04/01/1987 - "Aztreonam merits further evaluation in a randomized, comparative trial with standard antibiotic therapy for cystic fibrosis." 11/01/2012 - "Aztreonam reduced the cfu of some strains by ∼1 log unit without preserving the integrity of cystic fibrosis airway cell monolayers, while decreasing the biofilms of other clinical isolates by ∼4 log units and protecting the monolayers from being compromised. "
4.	Respiratory Tract Infections (Respiratory Tract Infection) 11/01/1985 - "Aztreonam is effective for the treatment of lower respiratory tract infections due to susceptible gram-negative bacilli." 11/01/1985 - "Aztreonam was shown to be clinically effective in the treatment of lower respiratory infections due to P. " 11/01/1985 - "In this trial aztreonam was effective and safe for treatment of lower respiratory tract infections caused by P. " 03/01/1994 - "This study demonstrates that aztreonam can be administered as one component of a synergistic monobactam-aminoglycoside therapy in the treatment of nosocomial lower respiratory tract infections involving P aeruginosa." 11/01/1985 - "[Clinical study of aztreonam on respiratory tract infections caused by gram-negative pathogens]."
5.	Pneumonia (Pneumonitis) 06/01/1988 - "Aztreonam, the first clinically available monobactam antibiotic, achieves high serum levels and adequate levels in bronchial secretions and lung parenchyma for efficacy against most Gram-negative pathogens implicated in nosocomial pneumonias. " 08/01/1989 - "Clinical and microbiologic response rates were similar, except that only 5 of 11 patients with pneumonia were considered to be clinically cured with aminoglycoside therapy, while 5 of 6 patients with pneumonia treated with aztreonam were cured. " 01/01/1993 - "This trial shows that aztreonam is an effective agent with an excellent safety profile when used in combination regimens for the empiric treatment of pneumonia. " 03/23/1990 - "Clinical study supports the usefulness of aztreonam against gram-negative nosocomial pneumonia. " 01/01/1993 - "In the 59 patients with documented aerobic gram-negative pneumonia, microbiologic eradication rates were 72% in the aztreonam group versus 57% in the control group (P = 0.359). "

Related Drugs and Biologics

1.	Gentamicins (Gentamicin)
2.	Vancomycin
3.	Ceftazidime (Fortum)
4.	Anti-Bacterial Agents (Antibiotics)
5.	Clindamycin (Cleocin)
6.	Piperacillin
7.	Penicillins (Penicillin)
8.	Ampicillin (Omnipen)
9.	Norfloxacin
10.	tigecycline (Tygacil)

Related Therapies and Procedures

1.	Drug Therapy (Chemotherapy)
2.	Continuous Ambulatory Peritoneal Dialysis (CAPD)
3.	Aftercare (After-Treatment)
4.	Intramuscular Injections
5.	Renal Dialysis (Hemodialysis)